A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...

Moderna, Inc.'s stock soars 16% amid patent win over Pfizer/BioNTech, while legal battles highlight mRNA challenges. Click ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...

The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

-- A German court in Duesseldorf ruled that Pfizer and partner BioNTech broke a coronavirus vaccine patent held by Moderna, Reuters reports. -- The court said Pfizer and BioNTech would have to provide ...

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...